الملخص
Resumen: La pandemia actual generada por el nuevo coronavirus (SARS-CoV-2) ha constituido desde su aparición, el foco de preocupación sanitaria a nivel mundial. Su elevada transmisibilidad asociada a la ausencia de un tratamiento eficaz, implica un duro impacto en el área de investigación. Los reportes sobre formas de presentación atípicas, factores de riesgo asociados y fármacos ensayados para disminuir su morbimortalidad, saturan los medios de comunicación. La comunidad cardiológica se encuentra activamente presente, ya que las manifestaciones cardiovasculares son frecuentes y variadas, así como también se ha observado un aumento del riesgo de mala evolución en aquellos individuos con enfermedad cardiovascular previa. El objetivo de la revisión es aportar la evidencia disponible en este tópico, haciendo la salvedad del carácter dinámico de la información.
Summary: The current pandemic caused by the new coronavirus (SARS-CoV-2) has been the focus of global health concern since its appearance. Its high transmissibility associated with the absence of an effective treatment implies a hard impact in the research area. Reports of atypical presentation forms, associated risk factors, and drugs tested to decrease morbidity and mortality saturate the media. The cardiology community is actively present since cardiovascular manifestations are frequent and varied, as well as an increased risk has been observed in those patients with previous cardiovascular disease. The objective of this review is to contribute the available evidence on this particular topic, making the caveat, of the dynamic nature of the information.
Resumo: A atual pandemia causada pelo coronavírus (SARS-CoV-2) tem sido o foco de preocupações globais com a saúde desde o seu surgimento. Sua alta transmissibilidade associada à ausência de um tratamento efetivo implica forte impacto na área de pesquisa. Relatos de formas de apresentação atípicas, fatores de risco associados e medicamentos testados para diminuir a morbimortalidade saturam a mídia. A comunidade de cardiologia está ativamente presente, pois as manifestações cardiovasculares são frequentes e variadas, bem como um risco aumentado foi observado nos pacientes com doença cardiovascular anterior. O objetivo desta revisão é contribuir com as evidências disponíveis sobre esse tópico em particular, tornando a advertência da natureza dinâmica das informações.
الملخص
Resumen: El Congreso Europeo de Cardiología constituye uno de los eventos más relevantes de la comunidad cardiológica mundial. Fue realizado entre el 31 de agosto y el 4 de setiembre en el corazón de París, siendo el tema central la salud cardiovascular global. Como es habitual, contó con la presencia de más de 30.000 profesionales y destacados invitados. Se presentaron actualizaciones de varias guías de práctica clínica e importantes trabajos científicos que sin duda impactarán en el tratamiento de los pacientes con patología cardiovascular. A continuación realizaremos un breve resumen de algunos de los trabajos presentados: - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial
Summary: The European Congress of Cardiology is one of the most relevant events of the world cardiology community. It was held from August 31 to September 4 in the heart of Paris, France, the central theme being global cardiovascular health. As usual, it was attended by more than 30,000 professionals and prominent guests. Updates of several clinical practice guides and important scientific papers were presented. These undoubtedly will impact in the treatment of patients with cardiovascular pathology. Below we present a brief summary of some of the trials presented: - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial
Sumário: O Congresso Europeu de Cardiologia é um dos eventos mais relevantes da comunidade mundial de cardiologia. Foi realizada de 31 de agosto ao 4 de setembro no coração de Paris, na França, o tema central foi a saúde cardiovascular global. Como sempre, participaram mais de 30.000 profissionais e convidados de destaque. Atualizações de vários guias de prática clínica e importantes artigos científicos foram apresentados que, sem dúvida, impactarão o tratamento de pacientes com patologia cardiovascular. Abaixo, faremos um breve resumo de alguns trials apresentados: - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial
الملخص
Resumen: Como todos los años, en esta oportunidad se celebró el 68º Congreso del Colegio Americano de Cardiología (ACC, por su sigla en inglés) entre los días 16 y 18 de marzo en Nueva Orleans, Luisiana. Ambientado en la ciudad del Mardi Gras y el jazz, nuevamente convocó a la cardiología mundial para promover el conocimiento a través de la presentación de múltiples actividades científicas. Contó con la presencia de más de 16.000 asistentes y se recibieron 2.300 artículos, muchos de los cuales, sin duda, modificarán la práctica clínica actual. Cabe destacar, asimismo, la presentación de la Guía de Prevención Primaria de la Enfermedad Cardiovascular, donde resalta el casi total abandono del ácido acetilsalicílico en prevención primaria debido a la falta de beneficio neto. Realizaremos un breve resumen de algunos de los principales trabajos científicos presentados: - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI: The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch: The Apple Heart Study
Summary: As every year, on this occasion the 68th Congress of the American College of Cardiology was held from March 16 to 18 in New Orleans, Louisiana. Set in the city of Mardi Gras and jazz, it once again called on global cardiology to promote knowledge through the presentation of multiple scientific activities. It counted with the presence of more than 16.000 attendees and 2.300 articles were received, many of which will undoubtedly modify the current clinical practice. It is also worth mentioning the presentation of the Primary Prevention of Cardiovascular Disease Guideline, which highlights the almost total discontinuation of acetylsalicylic acid in primary prevention due to the lack of net benefit. We will make a brief summary of some of the main scientific papers presented: - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI: The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch: The Apple Heart Study
Resumo: Como todos os anos, nesta ocasião, o 68º Congresso do Colégio Americano de Cardiologia (ACC após sua sigla em inglês) foi realizado de 16 a 18 de março em Nova Orleans, Louisiana. Situado na cidade do Mardi Gras e jazz, mais uma vez convidou a cardiologia do mondo para promover o conhecimento através da apresentação de múltiplas atividades científicas. Contou com a presença de mais de 16.000 participantes e 2.300 artigos recebidos, muitos dos quais sem dúvida modificarão a prática clínica atual. Também vale ressaltar a apresentação da Diretriz para a Prevenção Primária de Doenças Cardiovasculares, que destaca o quase total abandono do ácido acetilsalicílico na prevenção primária devido à falta de benefício líquido. Faremos um breve resumo de alguns dos principais trabalhos científicos apresentados: - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI: The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch: The Apple Heart Study
الملخص
Resumen: El 34° Congreso Uruguayo de Cardiología, celebrado en Montevideo del 2 al 4 de diciembre del pasado año, nuevamente destacó por las excelentes presentaciones de los temas más relevantes del ámbito cardiológico, así como también por sus invitados de renombre, nacionales e internacionales. Acompañando el gran nivel del Congreso se expusieron 32 temas libres que abarcaron diferentes áreas de la cardiología de los cuales comentaremos cuatro trabajos premiados: - Riesgo de trombosis en bioprótesis aórtica y eventos clínicos según uso de anticoagulación. Metaanálisis de la evidencia actual. - Uso de NT-ProBNP como predictor de evolución en el posoperatorio de cirugía cardíaca. - Prevalencia de septal pouch en una cohorte derivada para ecocardiograma transesofágico. - Incidencia de troponina T ultrasensible en rango anormal y su correlación con la anatomía coronaria en pacientes en valoración por enfermedad coronaria estable.
Summary: The 34th Uruguayan Congress of Cardiology, celebrated last year in Montevideo from December 2nd to 4th, again stood out for the excellent presentations of the most relevant topics in the field of cardiology, as well as for its renowned national and international guests. Accompanying the great level of the Congress, 32 articles that covered different topics in the cardiological area were presented, of which we will comment four awarded: - Risk of thrombosis in aortic bioprosthesis and clinical events according to the use of anticoagulation. Meta-analysis of current evidence. - Use of NT-ProBNP as a predictor of evolution in the postoperative period of cardiac surgery. - Prevalence of septal pouch in a cohort derived for transesophageal echocardiography. - Incidence of ultrasensitive troponin T in abnormal range and its correlation with coronary anatomy in patients in assessment for stable coronary disease.
Resumo: O 34º Congresso Uruguaio de Cardiologia, realizado em Montevidéu entre os dias 2 e 4 de dezembro no ano passado, voltou a destacar-se pelas excelentes apresentações dos temas mais relevantes no campo da cardiologia, bem como por seus renomados convidados, nacionais e internacionais. Acompanhando o grande nível do Congresso, tinham 32 temas livres que cobriam diferentes áreas da cardiologia, dos quais comentaremos quatro artigos premiados: - Risco de trombose na bioprótese aórtica e eventos clínicos de acordo com o uso de anticoagulação. Meta-análise da evidência atual. - Uso de NT-ProBNP como preditor de evolução no pós-operatório de cirurgia cardíaca. - Prevalência de bolsa septal em uma coorte derivada para ecocardiografia transesofágica. - Incidência de troponina T ultrassensível em faixa anormal e sua correlação com a anatomia coronariana em pacientes em avaliação para doença coronariana estável.
الملخص
Resumen: El Congreso Europeo de Cardiología se llevó a cabo en la ciudad de Múnich del 25 al 29 de agosto. Sin duda, uno de los eventos más importantes e innovadores de la comunidad cardiológica reunió a más de 32.000 profesionales, con destacados invitados internacionales y múltiples actividades científicas. Además de las tradicionales presentaciones de estudios, se inauguró un área de Salud Digital: Digital Health Area donde se llevaron a cabo sesiones continuas sobre E-Cardiology, con múltiples presentaciones de apps móviles, telemedicina y tecnología digital tanto para los profesionales como para la comunidad. Se presentaron las nuevas guías europeas sobre Hipertensión Arterial, tan esperadas luego del debate planteado en relación con las guías americanas en 2017. Las pautas europeas se mantendrán dentro del umbral de diagnóstico de 140/90 mmHg y se centrarán en mejorar las tasas de control a través de combinaciones iniciales de dos fármacos antihipertensivos para la mayoría de los pacientes. Realizaremos un breve resumen de algunos de los principales trabajos científicos presentados: - Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease: ARRIVE. - Coronary CT Angiography and 5-Year Risk of Myocardial Infarction: The SCOT-HEART Investigators. - Partial Oral Treatment of Endocarditis: POET. - Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: GLOBAL LEADERS. - One-Year Outcomes after PCI Strategies in Cardiogenic Shock: CULPRIT-SHOCK.
Summary: The European Congress of Cardiology was held at Munich from August 25th to 29th. Undoubtedly one of the most important and innovative events of the cardiology community, it brought together more than 32.000 professionals, with prominent international guests and multiple scientific activities. In addition to the traditional presentations of studies, ESC 2018 inaugurated a: Digital Health Area, where continuous sessions on E-Cardiology were held with multiple presentations of mobile apps, telemedicine and digital technology for both, the professionals and the community. The new european guidelines on Arterial Hypertension, awaited after the discussion related with the American guidelines in 2017, were presented. European blood pressure guidelines will stick with the 140/90 mmHg diagnostic threshold and will focus on improving control rates through initial two-drug antihypertensive combinations for most patients. We will make a brief summary of some of the main scientific trials presented: - Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease: ARRIVE. - Coronary CT Angiography and 5-Year Risk of Myocardial Infarction: The SCOT-HEART Investigators. - Partial Oral Treatment of Endocarditis: POET. - Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: GLOBAL LEADERS. - One-Year Outcomes after PCI Strategies in Cardiogenic Shock: CULPRIT-SHOCK
الملخص
Resumen: La fibrilación auricular (FA) aumenta el riesgo de accidente cerebrovascular (ACV) y tromboembolia (TE) sistémica, por lo que resulta fundamental prevenir esta temible complicación a través del tratamiento anticoagulante. Al uso habitual de warfarina se agregaron en los últimos años los anticoagulantes orales directos (ACOD). Frente a una intervención, o procedimiento invasivo es necesario evaluar el riesgo embólico y el de sangrado para definir el manejo más adecuado de estos fármacos. En el presente artículo se proponen recomendaciones para el tratamiento anticoagulante periprocedimiento en la fibrilación auricular no valvular basadas en el consenso de expertos del American College of Cardiology.
Summary: Atrial fibrillation increases the risk of stroke and systemic embolism, so it is important to prevent this terrible complication with anticoagulant therapy. To the usual use of warfarin were added in recent years, direct anticoagulants. In front of an invasive procedure, it is necessary to evaluate embolism and bleeding risks to define the most appropriate management of these drugs. In the present article, recommendations based in expert consensus of American College of Cardiology are proposed, to periprocedural anticoagulation treatment in non-valvular atrial fibrillation.
الملخص
Resumen: Del 10 al 12 de marzo de este año se celebró la reunión número 67 del congreso anual del American College of Cardiology (ACC), la cual tuvo lugar en el Orange County Convention Center, de la ciudad de Orlando, Florida. Sin duda, uno de los eventos más destacados de la agenda cardiológica, contó con la participación de más de 13.000 profesionales, con destacados invitados internacionales y múltiples actividades científicas. Uno de los puntos más esperados del evento fue la presentación de los ensayos clínicos; entre los 2.719 resúmenes aceptados, fueron 20 los trabajos seleccionados para ser presentados en las sesiones de Late Breaking Clinical Trials y 17 en las sesiones de Investigación Clínica1,2,3. Realizaremos un breve resumen de algunos de los principales trabajos científicos presentados. ( The ODYSSEY Outcomes Trial. Alirocumab in Patients After Acute Coronary Syndrome. ( Vest Prevention of Early Sudden Death Trial (VEST). ( TREAT Trial. Ticagrelor vs. Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. ( NOTION. Five-Year Outcomes From the All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial in Patients with Severe Aortic Valve Stenosis. ( Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing.
Summary: From March 10 to 12 of this year, the 67th annual meeting of the American College of Cardiology (ACC) was held at the Orange County Convention Center in Orlando, Florida. Undoubtedly, one of the most outstanding events of the cardiological agenda, was attended by more than 13.000 professionals, with prominent international guests and multiple scientific activities. One of the most awaited points of the event was the presentation of the clinical trials; among the 2.719 accepted abstracts, there were 20 works selected to be presented in the Late Breaking Clinical Trials sessions and 17 in the Clinical Research sessions1,2,3 We will make a brief summary of some of the main scientific trials presented: ( The ODYSSEY Outcomes Trial. Alirocumab in Patients After Acute Coronary Syndrome. ( Vest Prevention of Early Sudden Death Trial (VEST). ( TREAT Trial. Ticagrelor vs. Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. ( NOTION: Five-Year Outcomes From the All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial in Patients with Severe Aortic Valve Stenosis. ( Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing.